CRISPR Therapeutics (NASDAQ:CRSP) gains visibility as biotechnology activity aligns with broader movements across the Nasdaq ...
Comparing the genomes of snakes with distinct coloration patterns pinpointed the genetic variants that contribute to these ...
Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...
DUBLIN--(BUSINESS WIRE)--ERS Genomics Limited (‘ERS’) is pleased to announce ATLATL Innovation Centre (‘ATLATL’) as its non-exclusive agent for licensing ERS’ intellectual property for commercial ...
AZoLifeSciences on MSN
Gene scissors in camouflage mode help in the search for cancer therapies
The immune system plays a crucial role in fighting tumours and metastases. Consequently, it is decisive to conduct cancer research in mouse models with an immune system that is as natural as possible ...
Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex ...
TipRanks on MSN
CRISPR Therapeutics AG: Stock surge amid challenges
Crispr Therapeutics AG ( ($CRSP) ) has risen by 9.03%. Read on to learn why. Crispr Therapeutics AG has seen its stock price rise by 9.03% over ...
CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, RBC Capital raised its price target for CRISPR Therapeutics AG (NASDAQ:CRSP ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback